Clinical Trials · NCT07487363
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Hudson Biotech
- Enrollment
- 80
- Start date
- Feb 2026
- Locations
- 1 site, China
- Primary endpoint
- incidence of treatment-emergent adverse events (TEAEs)